Exact Sciences Officer Plans $90K Stock Sale via 10b5-1 Plan
EXACT SCIENCES CORP
Subscribe to track EXAS
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Exact Sciences Officer Plans $90K Stock Sale via 10b5-1 Plan
Company: EXACT SCIENCES CORP (EXAS) Form: 144 | Filed: 2025-10-09 Significance: Low
Insider: Herriott James Title: Officer | Relationship: Officer
Transaction: • Type: Proposed Sale • Shares: 1,500 • Price: $60.00 • Value: $90,000 • Owned After: Not Available
Key Insight: This is a notice of a proposed sale by an officer. The transaction is relatively small and is being conducted under a pre-scheduled 10b5-1 trading plan adopted in March 2025, which significantly reduces its informational value.
Market Context: Pre-planned sales by insiders are common for liquidity and diversification and are generally not seen as a bearish indicator.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: EXACT SCIENCES CORP (EXAS)
Executive Summary
- Trading Significance: Low
- Key Takeaway: An officer at Exact Sciences has filed a notice of a proposed sale of common stock valued at $90,000. The sale is planned under a 10b5-1 trading plan, indicating it was pre-scheduled and likely not based on new material non-public information.
- Market Impact: The market impact is expected to be neutral to negligible due to the small transaction size and its execution under a 10b5-1 plan.
Company Information
| Field | Value |
|---|---|
| Company | EXACT SCIENCES CORP |
| Ticker Symbol | EXAS |
| CIK | 0001124140 |
| Industry | SERVICES-MEDICAL LABORATORIES [8071] |
Insider Information
| Field | Value |
|---|---|
| Name | Herriott James |
| CIK | 0001957680 |
| Title/Position | Officer |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 |
| Transaction Date | 2025-10-09 (Approximate Sale Date) |
| Transaction Code | S (Sale) |
| Security Type | Common Stock |
| Shares Involved | 1,500 |
| Price Per Share | $60.00 (calculated) |
| Total Value | $90,000.00 |
| Shares Owned After | Not Available |
| Ownership Type | Not Specified |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: Form 144 filings for sales under a 10b5-1 plan are routine. The value of $90,000 is immaterial for a multi-billion dollar company. This type of transaction is typically for personal financial planning (diversification, liquidity) and does not signal a change in the insider's outlook on the company.
Volume & Sentiment
- Expected Volume Impact: Negligible. The 1,500 shares are a tiny fraction of the daily trading volume for EXAS.
- Sentiment Indicator: Neutral. The market generally disregards small, pre-planned insider sales.
Investment Insights
Positive Market Indicators
- The sale is not a spontaneous decision, which mitigates concerns about the insider acting on negative information.
Risk Factors
- While this specific transaction is low-risk, investors should monitor for a pattern of larger or more frequent sales from multiple insiders, which could collectively signal a concern.
Key Takeaways
- Pre-Planned Sale: The sale is pursuant to a 10b5-1 trading plan adopted on March 3, 2025, well in advance of the proposed sale date.
- Low Financial Impact: The $90,000 value is not significant enough to imply a strong opinion from the insider about the company's future prospects.
- Routine Filing: This Form 144 is a notice of intent to sell and is a standard procedure for affiliates selling restricted stock.
Contextual Analysis
Timing Significance
The filing indicates a proposed sale date that coincides with the filing date. The key timing element is the plan adoption date (March 3, 2025), which establishes that the decision to sell was made months prior.
Transaction Context
The filing explicitly notes a 10b5-1 plan adoption date. This is a critical piece of context, as it provides an affirmative defense against accusations of trading on inside information. The shares were originally acquired as part of compensation (Restricted Stock Vesting).
Company Context
Exact Sciences is a major player in the molecular diagnostics space, known for its Cologuard and Oncotype DX tests. Any analysis should consider the company's recent performance, product pipeline, and competitive landscape. This small insider sale is unlikely to be related to any major corporate developments.
Risk Assessment
Risk Level: Low
Risk Factors
- Misinterpretation: An uninformed investor might see 'insider sale' and interpret it negatively without understanding the context of a 10b5-1 plan.
- Size: The transaction size is too small to be a reliable indicator.
- Nature of Filing: A Form 144 is a notice of proposed sale, not a confirmation that the sale has occurred at the specified price.
Market Considerations
- Market Volatility: In a highly volatile market, even small insider sales can be scrutinized, but the 10b5-1 context should temper any overreaction.
- Sector Trends: The performance of the broader biotech and diagnostics sector can influence how such a filing is perceived.
- Company Performance: The sale should be viewed against the backdrop of the company's recent stock performance and financial results.
IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.
Analysis generated on 2025-10-09 | Data source: SEC EDGAR
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.